Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — Investor Day (2023)

57 slides from Aspen Pharmacare's investor day presentation, 2023

  1. Slide 1: Capital Markets Day 2023 – NDB Site Visit

    CAPITAL MARKETS Day 2023 ey ASPEN | NDB Site Visit

  2. Slide 2: Disclaimer

    DISCLAIMER CAUTIONARY REGARDING FORWARD-LOOKING STATEMENTS  We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward looking statements as defined in the U.

  3. Slide 3: Background and Objective

    Stephen Saad Group Chief Executive BACKGROUND AND OBJECTIVE

  4. Slide 4: Capital Markets Day: Background and Objectives

    Capital Markets Day BACKGROUND AND OBJECTIVES o cal Insights into Our Manufacturing Expertise Opportunities created Demonstration of confidence in our ability to execute on them Settled Foundation Period of aggressive globalisation ai of business Scars and stars from the many lessons learnt Poised f

  5. Slide 5: Aspen's Strategic Journey in Sterile Manufacturing

    ASPEN’S STRATEGIC JOURNEY IN STERILE MANUFACTURING

  6. Slide 6: Vision for Sterile Manufacturing

    Vision For Sterile Manufacturing 8 YEARS IN THE MAKING Sustainable demand AREAS OF INVESTMENT Future shift towards biologicals First mover • Prefilled syringes and other advanced sterile strategic advantage technologies. • Anaesthetics Opportunity to increase • Vaccines & biologicals Vertical integr

  7. Slide 7: Patient Access & Commercial Imperatives - A Symbiotic Relationship

    Patient Access & Commercial Impertatives - A Symbiotic Relationship INCREASING PATIENT ACCESS PROVIDES THE FOUNDATION FOR SUSTAINABLE VOLUMES Strong Global Pharma Partnerships Alliances with governments and multilateral agencies ACCESS A CORE STRATEGY FOR 25 YEARS [eKee) Skilled and highly capable 6

  8. Slide 8: Ensuring Patient Access in Challenging Circumstances

    Ensuring Patient Access in Challenging Circumstances OUR TIMELINE JOURNEY MDR TB PAEDIATRIC VACCINES Serum Partnership © Aspens first sterile facility investment © Partnership with Lilly for Capreomycin © Endorsed by GAVI © Grant funding from BMGF and CEPI ©@ WHO endorsed programme 2007 2023 COT g =

  9. Slide 9: Anaesthetics

    Anaesthetics KEY ENABLER IN BUILDING ASPEN’S STERILE MANUFACTURING FOUNDATION Insourcing Strategy R5.6BN Capex Investment STRATEGIC VISION AS GUIDED SINCE 2020: VALUE SITS IN SPARE CAPACITY TO DRIVE SUPERIOR ROIC

  10. Slide 10: Building the Aspen NDB Prefilled Syringe House

    Building the Aspen NDB Prefilled Syringe House IMMEDIATELY AVAILABLE PFS CAPACITY TO MEET INCREASED DEMAND COMMERCIAL TRANSACTIONS GSK Thrombosis products (Arixtra & Fraxiparine) including Aspen NDB facility -2014 Mono-embolex Thrombosis product from Novartis in 2015

  11. Slide 11: Building the Aspen NDB Prefilled Syringe House

    Building the Aspen NDB Prefilled Syringe House IMMEDIATELY AVAILABLE PFS CAPACITY TO MEET INCREASED DEMAND RESHAPING AND EXPANDING CAPACITY CE

  12. Slide 12: Building the Aspen NDB Prefilled Syringe House

    Building the Aspen NDB Prefilled Syringe House IMMEDIATELY AVAILABLE PFS CAPACITY TO MEET INCREASED DEMAND

  13. Slide 13: Building the Aspen NDB Prefilled Syringe House: New Contracts 2023

    Building the Aspen NDB Prefilled Syringe House IMMEDIATELY AVAILABLE PFS CAPACITY TO MEET INCREASED DEMAND NEW CONTRACTS SECURED IN 2023 | INCLUDING mRNA TECHNOLOGY

  14. Slide 14: Building the Aspen NDB Prefilled Syringe House: Future Opportunities

    Building the Aspen NDB Prefilled Syringe House IMMEDIATELY AVAILABLE PFS CAPACITY TO MEET INCREASED DEMAND FUTURE OPPORTUNITIES

  15. Slide 15: Building the South African Sterile Houses: Suite 1

    Building the South African Sterile Houses SUITE 1: THE ORIGINAL HOUSE 2007 ONWARDS

  16. Slide 16: Building the South African Sterile Houses: Insourcing Anaesthetics

    Building the South African Sterile Houses INSOURCING ANAESTHETICS 2019-2026 Basis for new Sterile Facility investment (suite 2) Built at the highest spec to include vaccines and other biologicals

  17. Slide 17: Building the South African Sterile Houses: J&J COVID Vaccine

    Building the South African Sterile Houses J&J COVID VACCINE 2020 225m doses supplied Aspen on global stage

  18. Slide 18: Building the South African Sterile Houses: Serum Agreement

    EN Building the Spent African Sterile Houses UM AGREEM

  19. Slide 19: Building the South African Sterile Houses: Novo Agreement

    Building the South African Sterile Houses NOVO AGREEMENT 2023 !

  20. Slide 20: Building the South African Sterile Houses: Future Opportunities

    Building the South African Ster FUTURE OPPURTUNITIES

  21. Slide 21: Strong Medium Term Growth Outlook for Steriles

    8 Years On – Harvesting Stage STRONG MEDIUM TERM GROWTH OUTLOOK FOR STERILES FY27 - Additional upside potential FY29 R10bn Sterile FY26 target Capex spend incremental NHEPS R4.0bn contribution >R5.50/share FY26 R0.8bn anaesthetics insourcing Increased FCF from WCap light R3.0bn to 3.5bn contribution

  22. Slide 22: Insights into SA Operations

    Martin Pretorius Integration Director INSIGHTS INTO SA OPERATIONS

  23. Slide 23: South African Operation

    South African Operation ASPEN’S HERITAGE CAN BE TRACED BACK TO A BUSINESS WHICH COMMENCED TRADE IN PORT ELIZABETH IN 1850

  24. Slide 24: South African Operations: Capabilities & Capacities

    South African Operations: Capabilities & Capacities STERILE CAPACITIES: FILLING LINE CAPABILITY Vials (space for 3 more vial filling lines) Capabilities Ampoules Eyedrops Vial Vial/cartridge Vial Vial Capacity 2 lines 2 lines 1 line 1 line 1 line 2 lines Use Anaesthetics Exported to Anaesthetics Nov

  25. Slide 25: Sterile Capacity Expansion

    Sterile Capacity Expansion 1 _ . Single sterile platform meeting n Aim is to create synergy in ways of - global standards ! working, best practice implementation ! and leveraging the existing sterile presence 1 1 EQUIPMENT AND DESIGN PROCESS BASIC OPERATING PRINCIPLES SYNONYMOUS WITH WORLD CLASS STE

  26. Slide 26: Sterile Manufacturing: Value Proposition

    Sterile Manufacturing: Value Proposition CUSTOMISING ANAESTHETIC FACILITY TO CATER FOR INSULINS AND ANAESTHETICS

  27. Slide 27: ESG Initiatives: SA Operations

    ESG Initiatives: SA Operations SECURING SUPPLY WHILST POSITIVELY IMPACTING THE ENVIRONMENT Water Sustainability Steam Generation

  28. Slide 28: Water Sustainability

    Water Sustainability WATER CONSUMPTION CURRENT USAGE IS 800K LITRES/DAY Short Term 750k litres/day from borehole and water treatment plant Medium Term (18 months) Second borehole and treatment plant extension Long Term End state will be about 1 500k litres/day

  29. Slide 29: Steam Generation

    Steam Generation In line with the Group’s ESG goals; in 2021 we implemented a steam generation project to convert from heavy fuels to biomass for steam generation Benefits include: Emissions - 10 times less than current SA legal standard Reduction in CO2 emissions — approximately 8 500 tonnes/year ®

  30. Slide 30: Energy

    Energy ENSURING SUSTAINABLE COST-EFFECTIVE ELECTRICITY SUPPLY Short Term Rental diesel back-up power generation synchronized with the municipal supply ’ Medium Term (2025) 20 MW Refuse derived fuel (RDF) power generation plant, will be sufficient to be completely off the grid. » Full electricity sec

  31. Slide 31: Insights into NDB Operations

    INSIGHTS INTO NDB OPERATIONS

  32. Slide 32: NDB: Through The Ages

    NDB: Through The Ages

  33. Slide 33: NDB: Site Facilities

    NDB: Site Facilities |____ 3 API workshops : ie Certopatine, Nadroparine Fondaparinux PFS Production : Filling, & Inspection and Packaging a) BFS Production : Filling, Inspection and Packaging }é Laboratories Warehouse > Here we are A Spots of visit

  34. Slide 34: NDB: Site Facilities

    NDB: Site Facilities Prefilled Syringe Blow Fill Seal Anticoagulant API’s Anticoagulants Polyamps PE © O @ Diluents O Polyamps PP O mRNA Technology O Polybags © © Flu Vaccines Tech Transfer

  35. Slide 35: NDB: PFS Capacity

    NDB: PFS Capacity 3 PFS Lines with a Total of 350M Capacity 4 Inspection Lines 6 Packaging Lines © Committed and Current e Available

  36. Slide 36: NDB Capacities: BFS Rotary Filling Machines

    NDB Capacities: BFS 2 Rotary Filling Machines Total Capacity of 50 million 1 Filling Machine for Rigid Bags 3 Automated Leak Detection and Visual Inspection Lines 3 Terminal Autoclaves 2 Packaging Lines

  37. Slide 37: NDB Capacities: Laboratories & Warehouse

    NDB Capacities: Laboratories & Warehouse QUALITY AND TESTING 3 Divis = ° wr SS . e Wh \\ eP / O

  38. Slide 38: ESG Investment For A Sustainable Future

    ESG Investment For A Sustainable Future SECURING SUPPLY WHILST POSITIVELY IMPACTING THE ENVIRONMENT 40

  39. Slide 39: ESG Investment: Reduction in Water Consumption

    ESG Investment For A Sustainable Future REDUCTION IN WATER CONSUMPTION Two main changes in the water consumption reduction: Evolution of water consumption (m3) • Former filling building stopped and filling activities transferred in the new building T – Implementation of new recycling cleaning water

  40. Slide 40: ESG Investment: Lower GHG Emissions

    ESG Investment for Sustainable Future LOWER GHG EMISSIONS FY Actions Annual target FY24. Solar panel & Heat recovery BFS -5% FY25 Hot water system replacement (buid $/P) = 3% FY26 Biomass (boiler replacement) 48% FY27 Restaurant boiler replacement -1% FY28_ Heat recovery on chillers (buid 7) -3% FY2

  41. Slide 41: Defining Operational Excellence

    DEFINING OPERATIONAL EXCELLENCE

  42. Slide 42: Aspen Sterile Manufacturing Operations

    Aspen Sterile Manufacturing Operations

  43. Slide 43: Quality By Design

    Quality By Design A STRATEGIC APPROACH Non-negotiable in the pharmaceutical industry Compliance assured on an on-going basis @ Internal controls | _ 7 @ Regulators Behind every medicine lies an Pars @ Customers, supplier and intricate process, where ne prospective clients' audits precision and excel

  44. Slide 44: Demonstration of Quality: Fondaparinux API

    Demonstration of Quality FONDAPARINUX API Ensuring absence of chemical contaminants Assurance of purity @) Continuous improvement 65% PURITY PURIFIED PRODUCT PURE VS IMPURE TEST s =

  45. Slide 45: Demonstration of Quality

    Demonstration of Quality Y) Absence of physical contamination Gj Glass particles and glass delamination Ejected glass particle CQ Assurance of absence of particles in sterile products

  46. Slide 46: Our Sterile Operations Value Proposition

    Our Sterile Operations Value Proposition QUALITY FIRST AND FOREMOST CONSIDERATION OF OUR CUSTOMERS Quality is a core responsibility of any company. Healthcare providers, patients, consumers and customers expect the level of quality they are promised. By building quality into processes, a company mee

  47. Slide 47: Our Sterile Operations Value Proposition: We Make It Happen

    Our Sterile Operations Value Proposition WE MAKE IT HAPPEN Customer Recognition of Capability @ J&J called Aspen the ‘Jewel in the J&J crown’ during the Covid vaccine partnerships. ‘At the end of a very challenging year we wish to express our sincere thanks to the entire Aspen team for the exception

  48. Slide 48: The Aspen Value Proposition

    The Aspen Value Proposition EXECUTING ON OUR CAPACITY FILL STRATEGY A Jud llaborati ra Johnson & Johnson Announces spen concludes a collaboration agreement to i manufacture and make available four Aspen- Landmark Agreement to Enable its branded vaccines for Africa. COVID-19 Vaccine to be Manufacture

  49. Slide 49: Technical Transfer Testimony

    TECHNICAL TRANSFER TESTIMONY

  50. Slide 50: COVID-19 Technical Transfer

  51. Slide 51: Stephen Saad

    Stephen Saad Group Chief Executive

  52. Slide 52: Recap of Aspen Strategic Focus

    Recap of Aspen Strategic Focus al Commercial Pharma ex-China fifall © Settled business with high predictability @ Sustained organic performance @ Supplemented by transactions that leverage our current footprint @ Future pipelines also included: LATAM product portfolio and Lilly transactions cleared}

  53. Slide 53: Recap of Aspen Strategic Focus: Manufacturing

    Recap of Aspen Strategic Focus MANUFACTURING Critical success factor to our strategic vision and ambitions @ In spite of being a third of the size of Commercial Pharma @ Both commercially and socially @ Gives us the capability to enhance equitable access Fundamental shift in return on assets and mat

  54. Slide 54: Why Aspen?

    Why Aspen? PUNCHING WAY ABOVE OUR WEIGHT TO DELIVER ACCESS g o ©} sspeno First FDA MDR TB Over 1,000,000 225m COVID doses Realisation of Generic ARV HIV/ AIDS patients for Africa African ambition reached in Africa 3 : ny ° ny Kk Manufactured COVID Manufactured both 1st & 2nd line TB treatments vacci

  55. Slide 55: Sterile Manufacturing: Why Aspen?

    Sterile Manufacturing: Why Aspen? CLIENT BASE OF PHARMA GIANTS -AN ENDORSEMENT OF CAPABILITY AND PROCESS INTEGRITY Aspen is Highly Regarded @ Supported by historic and current customer base @ Our customer base represent some of the giants at the cutting edge of global pharma @ Every major multinatio

  56. Slide 56: Why Aspen - Future Opportunities?

    Why Aspen-Future Opportunities? RIGHT PLACE AT THE RIGHT TIME, WITH THE RIGHT CAPABILITIES © @ The increases in sterile demand for cartridges/prefilled syringe capabilities is unprecedented @ Machinery suppliers need more than 24 months Obesity/diabetes markets will need billions of weekly sterile d

  57. Slide 57: Why Aspen - It's in the DNA?

    Why Aspen - It’s in The DNA? Successful execution is fundamental to Manufacturing excellence is in our DNA delivering on existing and future opportunities Full focus on delivery of existing opportunities. Its not glamorous and glitzy, its more like scrumming Dark art, spending honest endeavour, push

Aspen Pharmacare Holdings — Investor Day (2023) on 6ix